| EDUCATIONAL FORUM |
|
| Year : 2006 | Volume
: 38
| Issue : 4 | Page : 231-237 |
Glucagon like peptide-1: A new therapeutic target for diabetes mellitus
SK Patel1, RK Goyal2, IS Anand1, JS Shah1, HU Patel1, CN Patel1
1 Shri Sarvajanik Pharmacy College, Near Arvind Baug, Mehsana-384001, Gujarat, India
2 L.M. College of Pharmacy, Navrangpura, Ahmedabad-380009, Gujarat, India
Correspondence Address:
S K Patel
Shri Sarvajanik Pharmacy College, Near Arvind Baug, Mehsana-384001, Gujarat
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.27018
Glucagon-like peptide-1 (GLP-1) is an endogenous peptide secreted from the gut in response to the presence of food. GLP-1 and its longer acting analog exendin-4 have multiple synergistic effects on glucose dependent, insulin secretion pathways of the pancreatic β-cell and on plasticity in neuronal cells. Recently the development of these peptides as a novel therapeutic strategy for non-insulin-dependent (type 2) diabetes mellitus and associated neuropathy has been the focus of much interest. Here we describe the biological actions of GLP-1 and its related analogs.
[FULL TEXT] [PDF]*
|
